$FEMYr/pennystocksGraduating Penny Stockbullish u/jciccare · 89d agono track record yet FEMY READY FOR THE POWER HOUR PUSH
Femasys received FDA approval for its modular PMA submission pathway for FemBloc, a non-surgical permanent birth control technology. The stock is positioned to move from current 2.65 toward resistance at 3.48 on this approval catalyst.
At post $2.71·Now $1.28-52.8% since postedas of Nov 16, 4:55 PM ET
1d+0.7%
3d+9.2%
1w+7.7%
1m-4.4%
3m—
6m—
1y—
Long 803,038 shares of FEMY
803,038 shares · 9.99% of class · 2026-08-10
Schedule 13D: Nantahala Capital Partners Limited Partnership disclosed a stake in FEMY
Nantahala Capital Partners Limited Partnership disclosed a 9.99% stake of 803,038 shares in FEMASYS INC. (FEMY) in a Schedule 13D filed 2026-08-17.
At post $2.16·Now $1.28-40.7% since postedas of Nov 16, 4:55 PM ET
1d+1.9%
3d+26.4%
1w+38.0%
1m+17.6%
3m-34.3%
6m—
1y—
FEMY SEC Filing Dropped
FEMY raised $12M in senior secured convertible notes at $0.73 and warrants at higher strikes ($0.81–$1.10), with insider participation from the CEO, CFO, and board member. The premium pricing and insider conviction suggest management confidence in execution, while the capital runway enables debt payoff and expansion without desperation financing.
At post $20.80·Now $1.28-93.8% since postedas of Nov 16, 4:55 PM ET
1d—
3d0.0%
1w-13.7%
1m-15.4%
3m-53.4%
6m-56.4%
1y-93.4%
“one Long hold”
$FEMY is doing good
Femasys is a biomedical company with innovative reproductive health products (FemBloc for permanent birth control and FemaSeed for fertility treatment) that address unmet market needs. The author views it as a long-term hold that is still undervalued.
At post $20.80·Now $1.28-93.8% since postedas of Nov 16, 4:55 PM ET
1d—
3d0.0%
1w-13.7%
1m-15.4%
3m-53.4%
6m-56.4%
1y-93.4%
FEMY (Femasys Inc.) – FDA Catalyst + Short Squeeze + Long-Term Growth Play
Femasys (FEMY) is a low-float, highly shorted ($28.5M market cap, 57% short ratio) small-cap med-tech that just received FDA approval to advance its FemBloc permanent birth control device into final trials. The combination of short-squeeze potential from high short volume and long-term upside from a tangible FDA-backed product pipeline addressing unmet women's health demand creates bullish setup for near-term momentum and potential multi-bagger valuation if trials progress.
At post $13.68·Now $1.28-90.6% since postedas of Nov 16, 4:55 PM ET
1d+22.1%
3d+52.0%
1w+37.6%
1m+31.6%
3m-24.6%
6m-43.9%
1y-89.5%
FEMY, original post removed due to no summary of the article posted
FDA approval for final FemBloc trial phase combined with $12M secured financing and potential $58M in additional warrant proceeds signals strong upside. Author expects stock to establish a baseline above $1 based on C-1 warrant exercise prices, supported by surging volume and decreasing short availability.
At post $13.14·Now $1.28-90.3% since postedas of Nov 16, 4:55 PM ET
1d+4.1%
3d+18.9%
1w+58.3%
1m+35.3%
3m-18.6%
6m-41.6%
1y-89.3%
Long 150,000 shares of FEMY
FEMY announcing earnings 11/6
FEMY has approved non-surgical contraception and IVF alternative products in a tiny $27M market cap. With analyst price targets of $6-8 and IPO price of $3.40, the stock offers substantial upside potential ahead of earnings on 11/6.
At post $13.14·Now $1.28-90.3% since postedas of Nov 16, 4:55 PM ET
1d+4.1%
3d+18.9%
1w+58.3%
1m+35.3%
3m-18.6%
6m-41.6%
1y-89.3%
“6.3k shares at an average of .64 (about 4k invested); recent tactical trim of ~900 profits and rebuy for more shares with plan to trim on significant surges and rebuy at lower prices, eventually holding and adding to position long-term”
FEMY; my longterm bullish stance
FemBloc is a non-invasive permanent contraception procedure replacing tubal ligation with 95% effectiveness, lower cost (~$2500 cheaper), EMA/MEDSAFE approval, and a potential addressable market of 1.2M annual procedures. The author projects 20-38x upside over 3-10 years as the product becomes a new healthcare standard with no current competitors and multiple other FDA-approved revenue streams from Femasys.
At post $12.18·Now $1.28-89.5% since postedas of Nov 16, 4:55 PM ET
1d+3.9%
3d+3.9%
1w+2.0%
1m+51.1%
3m+4.9%
6m-31.5%
1y-87.7%
Why $FEMY is a longterm pick
Femasys' FemBloc is a first-in-class non-surgical permanent birth control device with strong revenue potential if it captures even 1% of the addressable market (~$150M annually), supported by insurance coverage incentives and European partnerships. Phase 3 trial completion in April 2027 could unlock significant upside for this micro-cap biotech.
At post $11.94·Now $1.28-89.3% since postedas of Nov 16, 4:55 PM ET
1d+8.7%
3d+2.7%
1w-7.7%
1m+74.2%
3m-0.3%
6m-28.0%
1y-82.9%
“Just got in with a decent position”
$FEMY, might be worth keeping an eye on🚀
Femasys has secured CE Mark approval for FemBloc, its first non-surgical permanent birth control system, with early European orders and U.S. FDA trials underway. Multiple near-term catalysts (revenue updates, European launches, clinical readouts) combined with recent $8M financing and Russell Microcap inclusion position this microcap for potential significant upside as products reach market.
At post $12.60·Now $1.28-89.8% since postedas of Nov 16, 4:55 PM ET
1d—
3d+33.2%
1w-2.7%
1m+1.1%
3m-8.6%
6m-33.8%
1y-83.7%